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OBJECTIVES We sought to assess whether skeletal muscle mass might be a predictor of peak oxygen
consumption (VO2) and relation of the ventilation to carbon dioxide production (VE/VCO2)
slope in patients with chronic heart failure (CHF) independent of clinical conditions,
neurohormonal activation and resting hemodynamics.
BACKGROUND A variety of abnormalities characterize skeletal muscle and contribute to exercise intolerance
in patients with CHF. Skeletal muscle mass is a determinant of peak VO2 both in healthy
patients and in patients with CHF, but there are no reports on the independent predictive
value of this parameter, which can be measured with great accuracy by whole-body dual
energy X-ray absorptiometry (DEXA). The influence of skeletal muscle mass on VE/VCO2
slope is not known either.
METHODS We prospectively evaluated 120 consecutive noncachectic patients with CHF. Every patient
underwent a cardiopulmonary exercise test, an echo-Doppler examination and an evaluation
of neurohormonal activation and body composition as assessed by DEXA.
RESULTS At the univariate analysis, New York Heart Association (NYHA) class (p , 0.0001), age
(p , 0.0001), male gender (p , 0.0001) and plasma renin (p , 0.0001) significantly related
with peak VO2. There was a significant correlation between lean mass and absolute peak VO2
(r 5 0.70, p , 0.0001) and VE/VCO2 slope (r 5 20.27; p , 0.01). At the multivariate
analysis, lean mass predicted peak VO2 and VE/VCO2 slope independently of NYHA
functional class, age, gender, neurohormonal activation and resting hemodynamics.
CONCLUSIONS Skeletal muscle mass is an independent predictor of peak VO2 and VE/VCO2 slope in stable
noncachectic patients with CHF. Future studies will determine whether an increase in
skeletal muscle mass in the individual patient might result in an improvement in parameters
of exercise capacity. (J Am Coll Cardiol 2001;37:2080–5) © 2001 by the American College
of Cardiology
Chronic heart failure (CHF) is a syndrome characterized by
impaired exercise capacity, fatigue and exertional dyspnea.
Cardiopulmonary exercise testing with measurement of
peak oxygen uptake (peak VO2) is a useful index of exercise
capacity and a strong prognostic marker in patients with
CHF (1). Classically, hemodynamic disturbances were
thought to be responsible for the reduction of exercise
capacity; however, there is only a poor correlation between
hemodynamic abnormalities at rest and peak VO2 (2,3).
Therefore, it is possible that noncardiac factors may con-
tribute to exercise intolerance in patients with CHF. A
separate abnormality has been found during cardiopulmo-
nary exercise testing in patients with CHF. For a given rate
of carbon dioxide production (VCO2), patients with CHF
ventilate at a higher level compared with normal subjects;
therefore, the rate of increase in ventilation (VE) per unit
increase in VCO2 (VE/VCO2 slope) is steeper in patients
with CHF compared with controls (4). This parameter
carries independent prognostic implications (5), but the
mechanisms leading to increased ventilation during exercise
in CHF are not fully understood yet.
A variety of skeletal muscle abnormalities develops in
patients with CHF (6–10), many of which relate to im-
paired functional status. Skeletal muscle mass is another
important determinant of exercise capacity in patients with
CHF (11), but its role in the pathophysiology of CHF has
not yet been adequately investigated. This parameter can be
very accurately measured by dual energy X-ray absorptiom-
etry (DEXA), which is a noninvasive, highly reproducible
and accurate technique (12). Nevertheless, there are no
reports on the independent predictive value of this param-
eter in determining exercise intolerance in stable, nonca-
chectic patients with CHF. Therefore, we aimed at assess-
ing: 1) whether skeletal muscle mass might predict exercise
capacity independently of clinical, hemodynamic and neu-
rohormonal parameters in patients with CHF without
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cardiac cachexia, and 2) the relationship between skeletal
muscle mass and VE/VCO2 slope in this group of patients.
METHODS
Study population. We studied 120 consecutive patients in
a stable clinical and nutritional status followed at our
Outpatient Heart Failure Clinic. Every patient had a left
ventricular ejection fraction (LVEF) ,45% and a duration
of heart failure of at least six months, was on standard
therapy for heart failure and on optimal diuretic dose. We
excluded patients with intermittent claudication, significant
pulmonary disease, inducible ischemia or other disorders
limiting exercise performance other than cardiac disease.
Patients with signs of pulmonary or peripheral edema or
ascites were not included in the study because fluid retention
would interfere with the measurement of body composition
(12). A clear relationship exists between cardiac cachexia
and skeletal muscle abnormalities (13). Therefore, we ex-
cluded patients with cardiac cachexia, defined as a nonin-
tentional weight loss .7.5% of previous normal weight over
a period of six months (14). The protocol was approved by
the local ethics committee, and every patient provided
written informed consent before the beginning of the study.
Cardiopulmonary exercise testing. All patients underwent
a symptom-limited bicycle ergometer exercise test at a
constant cadence of 60 rpm. A continuous ramp protocol
was used in which work rate was increased by 10 W/min.
Gas exchange was monitored during the exercise test with a
computerized metabolic cart (Vmax 229, SensorMedics,
Yorba Linda, California). Oxygen uptake, carbon dioxide
production, VE and respiratory exchange ratio were mea-
sured online every 10 sec using a standard inert gas dilution
technique. Peak VO2 was defined as the highest VO2
achieved during exercise and was expressed both in ml/
min/kg and in ml/min (absolute peak VO2). The slope of the
relation between ventilation and CO2 (VE/VCO2) was
calculated from the exercise data and taken as an index of
the ventilatory response to exercise (5).
Neurohormonal activation. Venous blood samples were
drawn on the day of the study after a 30 min supine rest in
a fasting state between 8 and 9 AM. The concentrations of
aldosterone and renin were measured by a sandwich radio-
immunoassay (Biochem Immuno System, Rome, Italy).
Plasma norepinephrine and epinephrine levels were mea-
sured by high performance liquid chromatography with
electrochemical detection. The reference values in our lab-
oratory are 3.9 to 49.3 mU/L for renin, 0.04 to 0.42 nmol/l
for aldosterone, 215 to 475 pg/ml for norepinephrine and
,520 pg/ml for epinephrine.
Echo-Doppler examination. A complete echo-Doppler
examination was performed immediately before the exercise
test. Left ventricular end-diastolic volume and end-systolic
volume (area-length method) and LVEF were measured
from an apical four-chamber view. Mitral E and A wave
velocities, E/A ratio and E wave deceleration time were
measured at the mitral flow Doppler examination. Cardiac
stroke volume was measured as the product of the left
ventricular outflow tract annulus area, and time velocity
integral was measured at the same level by pulsed wave
Doppler. Mean pulmonary artery pressure was calculated as
previously described (15). All measurements were obtained
from the average of three beats for sinus rhythm patients
and five beats for those with atrial fibrillation.
Body composition. Body composition was measured with
DEXA by using a total body scanner (QDR 2000, Hologic,
Bedford, Massachusetts). This scanner uses a constant
potential X-ray source and a cerium filter to produce two
stable radiation beams at 6.4 and 11.2 fJ. A series of
transverse scans is made from head to toe at 1-cm intervals
for a total scan time of 7 min. When the two beams pass
through the body, attenuation of the radiation depends on
mass and type of tissue. On the basis of the regional
attenuation, the total fat mass, total lean mass and lean mass
of the legs and arms are calculated (12). Appendicular lean
mass was calculated from the sum of the lean mass of arms
and legs (16). Lean and fat mass were expressed as absolute
values and as a percent of body weight.
Statistical analysis. Results are given as mean 6 standard
deviation for continuous variables and as median (interquar-
tile range) for nonparametric variables. Comparison in body
composition between men and women was made by using
Student t test. Univariate regression analyses were per-
formed in order to identify the relationship between vari-
ables. Significant predictors of peak VO2 and VE/VCO2 at
the univariate analysis were used in different multivariate
models to assess their independent predictive value. A
commercially available statistical software package was used
(STATA 4.0, Stata Corporation, College Station, Texas).
A p value ,0.05 was considered statistically significant.
RESULTS
The etiology of CHF was ischemic cardiomyopathy in 73
patients (61%), idiopathic dilated cardiomyopathy in 44
patients (37%) and valvular heart disease in three patients
(2%). The detailed results relative to clinical status, echo-
cardiography, neurohormonal activation and parameters of
exercise tolerance are summarized in Table 1. Twenty
patients (16%) were in New York Heart Association
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 chronic heart failure
DEXA 5 dual energy X-ray absorptiometry
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
VCO2 5 carbon dioxide production
VE 5 ventilation
VE/VCO2 5 relation of the rate of ventilation to
carbon dioxide production
VO2 5 oxygen consumption
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(NYHA) class I, 62 (52%) in class II, 36 (30%) in class III
and 2 (2%) were in class IV. A total of 93% of patients were
on an angiotensin-converting enzyme (ACE)-inhibitor; the
remaining patients were taking an angiotensin II receptor
blocker due to intolerance of ACE inhibitors. A total of
73% of the patients were on beta-blockers and 88% were on
diuretics.
Results of body composition for the entire population and
for men and women are summarized in Table 2. Mean body
mass index was 27.3 6 3.9. Obesity was common in the
population. A total of 38% of patients had .30% body fat,
and 9% had .40% body fat.
Predictors of peak VO2 and VE/VCO2. Univariate predic-
tors of peak VO2 are reported in Table 3. Age (p , 0.0001;
r 5 0.37), gender (p , 0.0001; r 5 0.37), renin (p , 0.05;
r 5 0.2), NYHA class (p , 0.0001; r 5 0.42), cardiac stroke
volume (p , 0.0001; r 5 0.3) and E/A ratio (p , 0.05; r 5
0.13) predicted absolute peak VO2. The relationship be-
tween appendicular lean mass and absolute peak VO2 is
shown in Figure 1. At the multivariate analyses (Table 4),
appendicular lean mass predicted peak VO2 independently
of age, gender, NYHA class and renin. In the same model,
gender lost its predictive power. We were able to predict
53% of the variability of peak VO2 in ml/min/kg and 66% of
the variability of absolute peak VO2 with this model.
The detailed results of univariate predictors of VE/VCO2
slope are reported in Table 3. At the multivariate analysis,
appendicular lean mass (p 5 0.02) predicted VE/VCO2
independently of age (p 5 0.03), aldosterone (NS) and
percentage of LVEF (p 5 0.02).
DISCUSSION
In this study we describe the role of skeletal muscle mass as
assessed by DEXA in determining impaired VO2 and
increased ventilatory response during exercise in noncachec-
tic patients with CHF. In our population, skeletal muscle
mass predicted peak VO2 and VE/VCO2 independently of
age, NYHA class, gender, resting hemodynamic and neu-
rohormonal activation. Only few echocardiographic param-
eters predicted peak VO2 at the univariate analysis, and none
of them predicted exercise capacity independently. This
confirms previous reports that found that resting hemody-
namics only poorly related with peak VO2 (17,18).
Role of skeletal muscle in the pathophysiology of CHF.
Biochemical, histological and functional changes character-
ize skeletal muscle of patients with CHF (6,8,19,20). Many
of these abnormalities closely relate to exercise intolerance
(6,19,21–23). These findings have fuelled the muscle hy-
pothesis (24), according to which many of the symptoms
present in CHF are due to changes in the periphery rather
than to central hemodynamics. Nevertheless, these param-
eters can only be obtained at the cost of high invasiveness
and, therefore, are not widely used.
Skeletal muscle mass is an important determinant of
exercise capacity in patients with CHF (11). The contribu-
tion of this parameter to exercise intolerance in patients
with CHF has not yet been adequately investigated due to
a lack of reliable measurement methods. Dual energy X-ray
absorptiometry scanning is a relatively new technology that
allows a very accurate, noninvasive and rapid estimate of
body composition (12). Our main finding is in accordance
with the work of Lang et al. (11) who described a significant
relationship between skeletal muscle mass of the legs and
peak VO2 in a population of ambulatory patients with CHF.
Unfortunately, this study focused on skeletal muscle mass as
the only predictor of peak VO2 and no data is available
Table 2. Body Composition of 120 Consecutive Patients With











Weight (kg) 74 6 12 79 6 12 67 6 12 , 0.001
Height (cm) 168 6 7 170 6 7 158 6 6 , 0.0001
Body mass index 27.3 6 3.9 27.4 6 3.9 26.7 6 4.4 NS
Total fat mass (kg) 22.6 6 7.6 22.1 6 7.4 24.8 6 7.4 NS
Total lean mass (kg) 51.5 6 8.2 53.4 6 6.7 38.5 6 6.4 , 0.0001
Appendicular lean
mass (kg)
20.2 6 3.7 21.1 6 3.1 14.6 6 2.9 , 0.0001
Legs lean mass (kg) 14.7 6 2.6 15.2 6 2.2 10.8 6 2.2 , 0.0001
Arms lean mass (kg) 5.6 6 1.2 5.9 6 1.1 3.8 6 0.9 , 0.0001
Lean % body weight 67.0 6 7.3 69.1 6 6.4 59.7 6 6.3 , 0.0001
Fat % body weight 28.7 6 7.3 27.9 6 6.4 37.5 6 6.4 , 0.0001
* Men versus women.
All data are given as mean 6 SD.
CHF 5 chronic heart failure.
Table 1. Clinical Characteristics of a Population of 120
Ambulatory Patients With CHF
Variable Mean 6 SD
Age (yr) 62.1 6 8.8
n (men/women) 105/15
NYHA functional class I–II (%) 82/120
Plasma creatinine (mmol/l) 100.2 6 26.4
Plasma sodium (mEq/l) 139.2 6 3.1
LVEF (%) 34 6 9
LVEDV (ml) 266 6 96
LVESV (ml) 182 6 87
DtE (ms) 222 6 82
E max (m/s) 0.6 6 0.2
A max (m/s) 0.7 6 0.2
E/A ratio 1.0 6 1.0
MPAP (mm Hg) 28.8 6 8.6
Stroke volume (ml) 85 6 9
Peak VO2 (ml/min/kg) 17.3 6 5.0
Absolute VO2 (l/min) 1327.7 6 470.4
VE/VCO2 slope 36.9 6 7.0
Rest SBP (mm Hg) 137 6 20
Plasma norepinephrine (ng/l) 336 (182–480)
Plasma renin (ng/l) 46 (12.3–100.8)
Plasma aldosterone (nmol/l) 0.25 (0.2–0.34)
Data are given as mean 6 SD or median (interquartile range).
A max 5 A wave velocity; ACE 5 angiotensin-converting enzyme; DtE 5 E
wave deceleration time; E max 5 E wave velocity; LVEDV 5 left ventricular
end-diastolic volume; LVEF 5 left ventricular ejection fraction; LVESV 5 left
ventricular end-systolic volume; MPAP 5 mean pulmonary artery pressure;
NYHA 5 New York Heart Association; SBP 5 systolic blood pressure; VE/VCO2 5
relation of the ventilation to carbon dioxide production, VO2 5 oxygen consumption.
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concerning clinical and hemodynamic parameters in this
population. Other authors (25) found a significant relation-
ship between peak VO2 and thigh muscle cross-sectional
area, but this finding is limited to a small number of
patients, and, as in other studies (6), it is not clear whether
cachectic patients were included. We believe this is impor-
tant to establish. In fact, the relationship between skeletal
muscle atrophy and functional impairment is well known
(13,26). Therefore, we excluded patients with cardiac ca-
chexia from the study.
Predictors of peak VO2. In our study at the univariate
analysis, gender was a strong predictor of peak VO2. On the
contrary, in a multivariate model including NYHA class,
age, appendicular muscle mass, total fat mass and gender,
the last parameter lost its predictive power. This suggests
that differences in exercise capacity between men and
women are probably due to differences in body composition.
In the same model, both muscle mass and total fat mass
were independent predictors of peak VO2, underlying the
importance of body composition in determining exercise
tolerance.
The relationship between skeletal muscle mass and peak
VO2 is quite clear. In fact, VO2 during maximal exercise
occurs almost exclusively in the exercising muscles as blood
is shunted away from the splanchic bed (27). On the
contrary, total fat mass has a negative relationship with peak
VO2, that is, the higher the fat content, the lower the
exercise capacity. These findings have potential clinical
implications, as the value of peak VO2 in defining functional
status and predicting outcome might be enhanced by
correcting absolute VO2 for skeletal muscle mass instead of
for total body weight. In a recent paper, Osman et al. (28)
reported the prognostic value of body fat adjusted peak VO2
compared with weight adjusted peak VO2 in a population of
225 patients with CHF. In their study, despite a nonoptimal
evaluation method of body composition, encouraging results
were found. In the future, an even more striking difference
between the two variables might be expected by evaluating
body composition with DEXA instead of the skinfold
technique. This correction might be particularly useful in
women and may increase the prognostic value of peak VO2
in this group of patients. Similar implications might concern
Table 3. Clinical Predictors of Peak VO2 in ml/min/kg, peak VO2 in ml/min and VE/VCO2 Slope in a Population of 120 Patients
With CHF (Univariate Analysis)
Peak VO2 (ml/min/kg) Peak VO2 (ml/min) VE/VCO2 Slope
Variable
p
Value b (95% CI) r
p
Value b (95% CI) r
p
Value b (95% CI) r
Age (yr) , 0.0001 20.2 (20.3 4 20.1) 0.38 , 0.0001 221.0 (230.5 4 211.5) 0.37 , 0.01 0.2 (0.1–0.3) 0.24
NYHA class , 0.0001 23.2 (24.3 4 22.0) 0.45 , 0.0001 2287.8 (2402.2 4 2173.4) 0.42 0.001 2.8 (1.1–4.6) 0.29
Gender , 0.0001 24.6 (27.3 4 22.0) 0.30 , 0.0001 2558.5 (2809.9 4 2307.1) 0.37 NS — —
Norepinephrine
(ng/l)
NS — — NS — — NS — —
Renin (ng/l) , 0.0001 20.01 (20.02 4 20.006) 0.30 , 0.05 20.9 (21.7 4 20.1) 0.19 NS — —
Aldosterone
(nmol/l)
0.014 27.1 (212.7 4 21.4) 0.23 NS — — , 0.05 9.1 (1.3–16.9) 0.22
LVEF (%) NS — — NS — — , 0.05 20.2 (20.3 4 20.22) 20.22
Stroke volume
(ml)
0.016 0.06 (0.01–0.11) 0.22 , 0.001 8.2 (3.5–12.8) 0.30 , 0.01 20.1 (20.2 4 20.3) 20.27
Cardiac output
(ml/min)
0.06 0.09 (20.05–0.2) 0.21 , 0.01 0.1 (0.03–0.2) 0.30 NS — —
LVEDV (ml) NS — — NS — — NS — —
LVESV (ml) NS — — NS — — NS — —
E/A ratio NS — — NS — — , 0.05 1.4 (0.2–2.7) 0.22
DtE (ms) NS — — NS — — NS — —
MPAP (mm Hg) 0.06 20.12 (20.26–0.04) 0.21 NS — — NS — —
Total lean mass (kg) , 0.0001 0.2 (0.1–0.3) 0.40 , 0.0001 0.03 (0.02–0.04) 0.67 , 0.01 20.2 (20.3 4 20.1) 20.24
Appendicular lean
mass (kg)
, 0.0001 0.6 (0.4–0.8) 0.46 , 0.0001 0.09 (0.07–0.1) 0.70 , 0.01 20.5 (20.8 4 20.1) 20.27
Leg lean mass (kg) , 0.0001 0.5 (0.3–0.7) 0.45 , 0.0001 0.08 (0.06–0.1) 0.71 , 0.01 20.3 (20.5 4 20.2) 20.23
Total fat mass (kg) 0.017 20.1 (20.2 4 20.02) 0.22 , 0.05 0.01 (0.001–0.02) 0.19 NS — —
CI 5 confidence interval. Other abbreviations as in Table 1.
Figure 1. Linear regression analysis between appendicular lean mass and
absolute peak oxygen consumption (VO2) in a population of 120 nonca-
chectic patients with chronic heart failure.
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the effect of age on peak VO2; in fact, it is well known that
the age-associated reduction in VO2 is related to the loss of
skeletal muscle (29).
Potential therapeutic implications. After considering the
relationship between skeletal muscle mass and exercise
capacity, one might hypothesize that peak VO2 would
increase after interventions directed towards the increase of
skeletal muscle bulk. Cardiac rehabilitation (30,31), human
growth hormone (32) and anabolic steroids (33) might
provide some benefits to the periphery. In a recent study,
Harrington et al. (34) showed beneficial effects of salbuta-
mol on skeletal muscle in patients with CHF. Randomized
studies are needed in order to define the possible effects of
these means on skeletal muscle mass and, consequently, on
functional capacity.
Ventilatory response to exercise and skeletal muscle
mass. Another important finding of this study was the
relationship between skeletal muscle mass and VE/VCO2
slope. Appendicular lean mass predicted VE/VCO2 slope
independently of LVEF, age and neurohormonal activation.
The increase of VE/VCO2 in patients with CHF carries
relevant clinical consequences as it predicts outcome inde-
pendently of peak VO2 (35). A variety of abnormalities
contribute to the increase in the ventilatory response to
exercise in patients with CHF including increased anatom-
ical dead space (36), ventilation-perfusion mismatch (37),
pulmonary vasoconstriction (38) and altered chemosensitiv-
ity (39). It is not easy to explain why a reduced skeletal
muscle mass is associated with a higher VE/VCO2. In a
small population Harrington et al. (40) observed that the
amount and type of the exercising muscle can influence the
VE/VCO2 in patients with CHF, possibly because of a
greater metabolic stress on a smaller group of active muscles.
A muscle metaboreflex has been recognized as a stimulation
to ventilation (41), and this reflex is increased in patients
with CHF (42). Therefore, this might represent the link
between skeletal muscle bulk and the abnormal ventilation
we observed in our study. An increase of skeletal muscle
mass might, theoretically, result in a decrease in ventilatory
drive during exercise in these patients.
CONCLUSIONS
Our study further supports the role of skeletal muscle in the
pathophysiology of CHF. Skeletal muscle mass is an im-
portant determinant of exercise capacity independent of
central hemodynamics, neurohormonal activation, gender
and age; furthermore, it relates to ventilatory response
during exercise. Therefore, it seems important for patients
with CHF to maintain a normal skeletal muscle mass in
order to avoid functional impairment. Whether an increase
of skeletal muscle mass would result in an improvement of
exercise capacity and a reduced ventilatory drive during
exercise needs to be confirmed by future studies.
Table 4. Predictors of Peak VO2 (ml/min/kg) and Absolute VO2 (ml/min) in a Population of
120 Patients With CHF (Multivariate Analyses)
Peak VO2 (ml/min/kg) Absolute Peak VO2 (ml/min)
Variable p Value b (95% CI) p Value b (95% CI)
NYHA class , 0.0001 22.3 (23.3 2 21.3) , 0.0001 2198.7 (2295.1 4 2102.3)
Gender , 0.0001 23.5 (25.8 2 21.2) , 0.0001 2389.2 (2598.7 4 2179.6)
Age (yr) , 0.0001 20.22 (20.3 2 20.14) , 0.0001 2199.3 (2272.7 4 2125.8)
Renin (ng/l) , 0.0001 20.01 (20.02 2 20.001) 0.01 20.9 (21.6 4 20.2)
Stroke volume (ml) NS — , 0.05 4.7 (1.1–8.0)
R2 5 0.47 R2 5 0.49
Variable p Value b (95% CI) p Value b (95% CI)
NYHA class , 0.0001 22.1 (23.1 4 21.2) , 0.0001 213.4 (219.5 4 27.3)
App. lean mass (kg) 0.009 0.3 (0.1 4 1) 0.002 20.8 (21.32 4 20.3)
Age (yr) , 0.0001 20.18 (20.26 4 20.1) , 0.0001 2149.8 (2224.3 4 275.3)
Renin (ng/l) , 0.0001 20.015 (20.02 4 20.008) , 0.0001 74.9 (56.7 4 93.2)
Gender NS — NS —
R2 5 0.50 R2 5 0.65
Variable p Value b (95% CI) p Value b (95% CI)
Age (yr) , 0.0001 20.19 (20.3 4 20.1) ,0.0001 213.3 (219.3 4 27.2)
Renin (ng/l) , 0.0001 20.01 (20.02 4 20.01) , 0.0001 20.95 (21.47 4 20.42)
NYHA class , 0.0001 22.0 (22.9 4 21.1) , 0.0001 2157.4 (2231.4 4 283.3)
App. lean mass (kg) , 0.01 0.4 (0.1 4 0.6) , 0.0001 70.4 (51.7 4 89.0)
Total fat mass (kg) , 0.01 20.1 (20.2 4 20.04) NS —
Gender NS — NS —
R2 5 0.53 R2 5 0.66
APP 5 appendicular; CHF 5 chronic heart failure; CI 5 confidence interval; NYHA 5 New York Heart Association; VO2 5
oxygen consumption.
2084 Cicoira et al. JACC Vol. 37, No. 8, 2001
Skeletal Muscle and Exercise Capacity in Heart Failure June 15, 2001:2080–5
Acknowledgment
The authors wish to thank Mrs. Barbara Lyon for revising
the English manuscript.
Reprint requests and correspondence: Dr. Mariantonietta
Cicoira, Divisione Clinicizzata di Cardiologia, Ospedale Civile
Maggiore, P.le Stefani, 1 37126 Verona, Italy. E-mail:
mariantonietta.cicoira@univr.it.
REFERENCES
1. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak oxygen
consumption for optimal timing of cardiac transplantation in ambu-
latory patients with heart failure. Circulation 1991;83:778–86.
2. Weber KT, Wilson JR, Janicki J, Likoff MJ. Exercise testing in the
evaluation of the patient with chronic heart failure. Am Rev Respir Dis
1984;129 Suppl:S60–2.
3. Franciosa JA, Park M, Levine TB. Lack of correlation between
exercise capacity and indexes of resting left ventricular performance in
heart failure. Am J Cardiol 1981;47:33–9.
4. Clark AL, Volterrani M, Swan JW, Coats AJ. The increased ventila-
tory response to exercise in chronic heart failure: relation to pulmonary
pathology. Heart 1997;77:138–46.
5. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and
prognostic significance of the ventilatory response to exercise in
chronic heart failure. J Am Coll Cardiol 1997;29:1585–90.
6. Mancini D, Walter G, Reichek N, et al. Contribution of skeletal
muscle atrophy to exercise intolerance and altered muscle metabolism
in heart failure. Circulation 1992;85:1364–73.
7. Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic
skeletal muscle changes to 31p-NMR skeletal muscle metabolic
abnormalities in patients with chronic heart failure. Circulation 1989;
80:1338–46.
8. Drexler H, Riede U, Mu¨nzel T, et al. Alterations of skeletal muscle in
chronic heart failure. Circulation 1992;85:1751–9.
9. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and
histology in ambulatory patients with long-term heart failure. Circu-
lation 1990;81:518–27.
10. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of
patients with chronic heart failure is associated with exercise intoler-
ance. J Am Coll Cardiol 1999;33:959–65.
11. Lang CC, Chomsky DB, Rayos G, et al. Skeletal muscle mass and
exercise performance in stable ambulatory patients with heart failure.
J Appl Physiol 1997;82:257–61.
12. Prior B, Cureton KJ, Modlesky CM, et al. In vivo validation of whole
body composition estimates from dual-energy x-ray absorptiometry.
J Appl Physiol 1997;83:623–30.
13. Anker SD, Swan JW, Volterrani M, et al. The influence of muscle
mass, strength, fatigability and blood flow on exercise capacity in
cachectic and noncachectic patients with chronic heart failure. Eur
Heart J 1997;18:259–69.
14. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk
factor for mortality in chronic heart failure. Lancet 1997;349:1050–3.
15. Weyman AE. Principles and Practice of Echocardiography. 2nd ed.
Philadelphia, PA: Lea & Febiger, 1994.
16. Heymsfield SB, Smith R, Auler M, et al. Appendicular skeletal muscle
mass: measurement by dual-photon absorptiometry. Am J Clin Nutr
1990;52:214–28.
17. Higginbotham MB, Morris KG, Conn EH, et al. Determinants of
exercise performance among patients with congestive heart failure.
Am J Cardiol 1983;51:52–60.
18. Szlachic J, Massie BM, Kramer BL, et al. Correlates and prognostic
implication of exercise capacity in chronic congestive heart failure.
Am J Cardiol 1985;55:1037–42.
19. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function
and its relation to exercise tolerance in chronic heart failure. J Am Coll
Cardiol 1997;30:1758–64.
20. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of
patients with chronic heart failure is associated with exercise intoler-
ance. J Am Coll Cardiol 1999;33:959–65.
21. Wilson JR, Mancini D, Dunkman WB. Exertional fatigue due to
skeletal muscle dysfunction in patients with heart failure. Circulation
1993;87:470–5.
22. Minotti JR, Pillay P, Oka R, et al. Skeletal muscle size: relationship to
muscle function in heart failure. J Appl Physiol 1993;75:373–81.
23. Vescovo G, Serafini F, Dalla Libera L, et al. Skeletal muscle myosin
heavy chains in heart failure: correlation between magnitude of the
isozyme shift, exercise capacity and as exchange measurement. Am
Heart J 1998;135:130–7.
24. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in
chronic heart failure: central role of the periphery. J Am Coll Cardiol
1996;28:1092–102.
25. Volterrani M, Clark AL, Ludman PF, et al. Predictors of exercise
capacity in chronic heart failure. Eur Heart J 1994;15:801–9.
26. Toth MJ, Gottlieb SS, Fisher ML, Poehlman ET. Skeletal muscle
atrophy and peak oxygen consumption in heart failure. Am J Cardiol
1997;79:1267–70.
27. Clausen JP. Effects of physical conditioning. A hypothesis concerning
circulatory adjustment to exercise. Scand J Clin Lab Invest 1969;24:
305–11.
28. Osman AF, Mehra MR, Lavie CJ, et al. The incremental prognostic
importance of body fat adjusted peak oxygen consumption in chronic
heart failure. J Am Coll Cardiol 2000;36:2126–31.
29. Fleg JL, Lakatta EG. Role of muscle loss in the age-associated
reduction in VO2 max. J Appl Physiol 1988;65:1147–51.
30. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients
with stable chronic heart failure: effects on cardiorespiratory fitness and
ultrastructural abnormalities of leg muscles. J Am Coll Cardiol
1995;25:1239–49.
31. Coats AJS, Adamopoulos S, Meyer T, et al. Effects of physical training
in chronic heart failure. Lancet 1990;335:63–6.
32. Osterziel KJ, Strohm O, Schuler J. Randomised, double-blind,
placebo-controlled trial of human recombinant growth hormone in
patients with chronic heart failure due to dilated cardiomyopathy.
Lancet 1998;351:1233–7.
33. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired
survival and immune and neuroendocrine activation. Chest 1999;115:
836–47.
34. Harirngton D, Chua TP, Coats AJS, et al. The effect of salbutamol on
skeletal muscle in chronic heart failure. Int J Cardiol 2000;75:257–65.
35. Francis DP, Shamim W, Ceri Davies L, et al. Cardiopulmonary
exercise testing for prognosis in chronic heart failure: continuous and
independent prognostic value from VE/VCO2 slope and peak VO2.
Eur Heart J 2000;21:154–61.
36. Buller NP, Poole-Wilson PA. Mechanism of the increased ventilatory
response to exercise in patients with chronic heart failure. Br Heart J
1990;63:281–3.
37. Uren NG, Davies SW, Agnew JE, et al. Reduction of mismatch of
global ventilation and perfusion on exercise is related to exercise
capacity in chronic heart failure. Br Heart J 1993;70:241–6.
38. Reindl I, Wernecke K-D, Opitz C, et al. Impaired ventilatory
efficiency in chronic heart failure: possible role of pulmonary vasocon-
striction. Am Heart J 1998;136:778–85.
39. Chua TP, Clark AL, Amadi AA, Coats J. Relation between chemo-
sensitivity and the ventilatory response to exercise in chronic heart
failure. J Am Coll Cardiol 1996;27:650–7.
40. Harrington D, Clark AL, Chua TP, et al. Effect of reduced muscle
bulk on the ventilatory response to exercise in chronic congestive heart
failure secondary to idiopathic dilated and ischemic cardiomyopathy.
Am J Cardiol 1997;80:90–3.
41. Piepoli M, Clark AL, Coats AJS. Muscle metaboreceptors in hemo-
dynamic, autonomic and ventilatory responses to exercise in men.
Am J Physiol 1995;269:H1428–36.
42. Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle
afferents to the hemodynamic, autonomic and ventilatory response to
exercise in patients with chronic heart failure: effects of physical
training. Circulation 1996;93:940–52.
2085JACC Vol. 37, No. 8, 2001 Cicoira et al.
June 15, 2001:2080–5 Skeletal Muscle and Exercise Capacity in Heart Failure
